Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:FIXXNASDAQ:LABPNASDAQ:VRCANASDAQ:VRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.35-12.3%$1.37$0.59▼$2.31$169.16M1.21.39 million shs4.06 million shsFIXXHomology Medicines$0.48$0.46▼$1.48$54.33M-0.1390,307 shs401,400 shsLABPLandos Biopharma$21.67+0.7%$11.73$2.50▼$21.87$67.61M0.1422,659 shs15,314 shsVRCAVerrica Pharmaceuticals$7.06+0.9%$5.64$2.86▼$7.76$299.49M1.88157,340 shs105,357 shsVRNAVerona Pharma$16.40+1.2%$16.53$11.83▼$23.81$1.33B0.4498,326 shs348,625 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics-12.34%-22.86%+4.65%+65.44%+80.00%FIXXHomology Medicines0.00%0.00%+107.71%+223.65%+83.27%LABPLandos Biopharma+0.74%+0.53%+226.36%+356.21%+621.37%VRCAVerrica Pharmaceuticals+0.86%-1.81%+48.63%+22.57%+13.14%VRNAVerona Pharma+1.23%+0.80%+5.60%-4.54%-25.45%Uncover this 2024 Hidden Gem (Ad)Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.308 of 5 stars3.51.00.00.03.01.70.0FIXXHomology Medicines1.4592 of 5 stars3.30.00.04.80.00.80.6LABPLandos Biopharma0.3267 of 5 stars1.03.00.00.03.00.80.6VRCAVerrica Pharmaceuticals3.8459 of 5 stars3.51.00.04.72.32.50.6VRNAVerona Pharma1.242 of 5 stars3.50.00.00.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$4.50233.33% UpsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideLABPLandos Biopharma2.00Hold$20.42-5.77% DownsideVRCAVerrica Pharmaceuticals3.00Buy$11.2559.35% UpsideVRNAVerona Pharma3.00Buy$33.60104.88% UpsideCurrent Analyst RatingsLatest FIXX, ATOS, LABP, VRNA, and VRCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/16/2024VRNAVerona PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.004/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/4/2024VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/1/2024VRNAVerona PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.001/22/2024VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00LABPLandos Biopharma$18M3.76N/AN/A$10.20 per share2.12VRCAVerrica Pharmaceuticals$5.12M58.49N/AN/A$0.47 per share15.02VRNAVerona Pharma$460K2,881.41N/AN/A$3.10 per share5.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)VRNAVerona Pharma-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/14/2024 (Estimated)Latest FIXX, ATOS, LABP, VRNA, and VRCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/A2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million 2/29/2024Q4 2023VRNAVerona Pharma-$0.23-$0.16+$0.07-$0.16N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A17.6117.61FIXXHomology MedicinesN/A7.257.25LABPLandos BiopharmaN/A6.096.09VRCAVerrica Pharmaceuticals2.224.554.49VRNAVerona Pharma0.2033.3333.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%FIXXHomology Medicines31.32%LABPLandos Biopharma49.06%VRCAVerrica Pharmaceuticals42.45%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%FIXXHomology Medicines16.10%LABPLandos Biopharma1.30%VRCAVerrica Pharmaceuticals41.50%VRNAVerona Pharma4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics11125.30 million115.53 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableVRCAVerrica Pharmaceuticals10042.42 million24.82 millionOptionableVRNAVerona Pharma7980.82 million76.94 millionOptionableFIXX, ATOS, LABP, VRNA, and VRCA HeadlinesSourceHeadlineVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandleramericanbankingnews.com - April 17 at 3:36 AMVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgradeamericanbankingnews.com - April 17 at 1:08 AMVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrademarketbeat.com - April 16 at 10:36 AMVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandlermarketbeat.com - April 16 at 8:33 AMVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%marketbeat.com - April 4 at 3:08 PMAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 28 at 4:07 AMWellington Management Group LLP Acquires 164,268 Shares of Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 19 at 4:54 AMVRNA Apr 2024 17.500 callfinance.yahoo.com - March 16 at 8:32 AMVRNA Apr 2024 15.000 callfinance.yahoo.com - March 16 at 3:31 AMAndrew Fisher Joins Verona Pharma as General Counselglobenewswire.com - March 4 at 2:00 AMBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipelinemarkets.businessinsider.com - March 1 at 1:10 PMVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:10 PM3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com - March 1 at 8:45 AMVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 29 at 11:18 AMVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:48 AMVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 10:48 AMVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 2:00 AMVerona Pharma earnings preview: what to expectmarkets.businessinsider.com - February 28 at 1:35 PMWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?finance.yahoo.com - February 25 at 12:52 PMVerona Pharma PLC ADRwsj.com - February 25 at 7:52 AMVRNA Mar 2024 15.000 putfinance.yahoo.com - February 17 at 7:46 PMVRNA Jun 2024 30.000 callfinance.yahoo.com - February 17 at 2:46 PMVerona Pharma: A Few Points From The Bull And Bear Caseseekingalpha.com - February 15 at 5:55 PMVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Updatefinance.yahoo.com - February 15 at 10:20 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Verona PharmaNASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.